Entrada Therapeutics/TRDA
$14.95
3.17%-
1D1W1MYTD1YMAX
About Entrada Therapeutics
Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a class of medicines, which engages intracellular targets that have long been considered inaccessible. The Company’s Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient delivery of a range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Through its proprietary, highly versatile and modular EEV platform (EEV Platform), the Company is building a robust development portfolio of therapeutic candidates. Its first two drug candidates, ENTR-601-44 and VX-670, are in clinical trials. VX-670 for dystrophy type 1 (DM1) is designed to block the triplet repeats in the messenger RNA (mRNA). ENTR-601-44 is in a Phase I clinical trial. The Company also announced the selection of additional clinical candidates within its Duchenne franchise, ENTR-601-45 and ENTR-601-50.
Ticker
TRDA
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology & Drugs
CEO
Dipal Doshi
Employees
160
Headquarters
Boston, United States
Website
www.entradatx.com
TRDA Metrics
BasicAdvanced
$479M
Market cap
22.62
P/E ratio
$0.63
EPS
-
Beta
-
Dividend rate
Price and volume
Market cap
$479M
52-week high
$18.44
52-week low
$10.62
Average daily volume
79K
Financial strength
Current ratio
2.381
Enterprise value to free cash flow
6.891
Management effectiveness
Return on assets (TTM)
4.76%
Return on equity (TTM)
9.41%
Return on investment (TTM)
7.06%
Valuation
Price to earnings (TTM)
22.623
Price to revenue (TTM)
2.941
Price to book
1.77
Price to tangible book (TTM)
1.778
Growth
Revenue change (TTM)
544.79%
Earnings per share change (TTM)
124.73%
What the Analysts think about TRDA
Analyst Ratings
Majority rating from 4 analysts.
Price Targets
Average projection from 2 analysts.
High $22.00
Low $20.00
$14.95
Current price
$21.00
Average price target
TRDA Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$59M
41.39%
Net income
$23M
-346.32%
Profit margin
39.59%
-274.25%
TRDA Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.78
$1.02
-$0.29
$0.68
-
Expected
-$0.69
-$0.74
-$0.17
-$0.59
$0.12
Surprise
13.04%
-238.63%
72.62%
-214.48%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Upcoming events
FAQs
What’s the current market cap for Entrada Therapeutics stock?
Entrada Therapeutics (TRDA) has a market cap of $479M as of May 16, 2024.
What is the P/E ratio for Entrada Therapeutics stock?
The price to earnings (P/E) ratio for Entrada Therapeutics (TRDA) stock is 22.62 as of May 16, 2024.
Does Entrada Therapeutics stock pay dividends?
No, Entrada Therapeutics (TRDA) stock does not pay dividends to its shareholders as of May 16, 2024.
When is the next Entrada Therapeutics dividend payment date?
Entrada Therapeutics (TRDA) stock does not pay dividends to its shareholders.
What is the beta indicator for Entrada Therapeutics?
Entrada Therapeutics (TRDA) does not currently have a Beta indicator.
What is the Entrada Therapeutics stock price target?
The target price for Entrada Therapeutics (TRDA) stock is $21, which is 40.47% above the current price of $14.95. This is an average based on projections from 2 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.
Buy or sell Entrada Therapeutics stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.